Specifically, while ENG performed better in taxane treatments in HER2+ breast cancer subtype, TGFBR3 performed better for taxane regimens in triple-negative breast cancer (TNBC) and serous ovarian cancer. Here, ERBB2 is linked to ovarian serous adenocarcinoma.